Sanofi India Q3'26 Profit Rises 22% to ₹158 Crore; Declares Interim Dividend of ₹75/Share
Sanofi India reported a 22% rise in Q3 2026 profit before tax to ₹158 crore, up from ₹130 crore in Q3 2025. The company declared an interim dividend of ₹75 per share. Net sales grew 4% YoY. The Diabetes portfolio saw 9% growth.
The declaration of a substantial interim dividend and strong financial performance, particularly in the core diabetes segment, are significant events likely to impact investor sentiment and the company's stock price.
The company reported significant profit growth, a favorable increase in profit margins, and declared an interim dividend, all positive indicators for shareholders.
Sanofi India Limited announced its financial results for the quarter and nine months ended September 30, 2026, following a Board Meeting held on October 29, 2026.
The company reported a profit before tax and exceptional items of ₹158 crore for Q3 2026, a 22% increase from ₹130 crore in the third quarter of 2025. Profit before tax as a percentage of net sales improved to 34% in Q3 2026, up from 29% in Q3 2025. This improvement was attributed to a favorable product mix, a one-off reversal of provisions, and disciplined cost management, leading to an 8% decrease in operating expenses compared to the same period last year.
The Board of Directors also declared an interim dividend of ₹75 per equity share for the financial year 2026. The company has fixed Thursday, November 5, 2026, as the record date for the payment of this interim dividend.
Sanofi India's domestic net sales grew by 2% and total net sales by 4% in Q3 2026 compared to Q3 2025. The Diabetes portfolio showed strong performance with 9% growth, maintaining a 55% market share in the Diabetes Injectable segment. Export sales also delivered good double-digit growth. The public sector business surged by 85% driven by new accounts.
Deepak Arora, Managing Director, highlighted the strong momentum in the diabetes business and the double-digit growth in Sanofi India's PAT (Year-to-Date). He also emphasized the company's commitment to giving back to communities through initiatives like the KIDS Program and Medical Mobile Units, which focus on diabetes awareness and Non-Communicable Diseases screening.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.